Skip to main content
No Evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis
Published Web Location
http://europepmc.org/articles/PMC3867330?pdf=renderNo data is associated with this publication.
Abstract
Objective: Preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) reduced HIV acquisition in the iPrEx trial among men who have sex with men and transgender women. Self-reported sexual risk behavior decreased overall, but
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.